STK38L
Serine/Threonine Kinase 38 Like
Gene Information Card
| Symbol | STK38L |
|---|---|
| Full Name | Serine/Threonine Kinase 38 Like |
| Gene Type | protein-coding |
| Chromosomal Location | 12p11.23 |
| NCBI Gene ID | 23012 ncbi.nlm.nih.gov/gene/23012 |
| Ensembl ID | ENSG00000111445 |
| UniProt ID | Q9Y2H1 |
| OMIM ID | 616437 |
| HGNC ID | 17858 |
| Aliases | NDR2, STK38L, FLJ13052 |
Description
STK38L (Serine/Threonine Kinase 38 Like), also known as NDR2, is a member of the NDR (nuclear Dbf2-related) family of serine/threonine kinases. It plays a role in cell cycle regulation, apoptosis, and cytoskeletal organization. STK38L is involved in the Hippo signaling pathway and can act as a tumor suppressor or oncogene depending on context.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Cancer (various types) | Dysregulation of STK38L expression or activity alters Hippo signaling, affecting cell proliferation and apoptosis. | COSMIC, ClinVar |
| Neurodevelopmental disorders | Mutations in STK38L may impair neuronal development through kinase activity disruption. | OMIM |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Brain | 12.3 | Medium |
| Heart | 8.5 | Low |
| Liver | 6.2 | Low |
| Kidney | 9.1 | Low |
| Testis | 15.7 | Medium |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| HEK293 | 10.5 | Moderate expression |
| HeLa | 8.2 | Moderate expression |
| A549 | 7.0 | Low expression |
| MCF7 | 6.5 | Low expression |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| p.R371W | Missense | <1% | Unknown functional impact |
| p.E186K | Missense | <1% | Potential loss of kinase activity |
| c.1123_1124insA | Frameshift | <0.5% | Loss of function |
Mutation functional classification
Loss of Function (LOF)
Frameshift and nonsense mutations predicted to truncate the kinase domain, leading to loss of catalytic activity.
Gain of Function (GOF)
Not well characterized; some missense variants may increase kinase activity but evidence is limited.
Dominant Negative (DN)
No dominant negative mutations reported in STK38L.
View complete mutation data：
Gene Ontology (GO)
| • protein serine/threonine kinase activity | • ATP binding |
| • cell cycle | • apoptotic process |
| • Hippo signaling | • cytoskeleton organization |
Pathways
• Hippo signaling pathway
• Regulation of actin cytoskeleton
Protein Summary
STK38L encodes a 465-amino acid serine/threonine kinase with an N-terminal kinase domain and a C-terminal regulatory domain. It is activated by MST1/2 kinases and MOB1 co-activators. The protein localizes to the cytoplasm and nucleus, regulating cell cycle progression, apoptosis, and actin dynamics. Post-translational modifications include phosphorylation at Thr444 and Ser281, which are critical for activity.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| STK38L Knockout HEK293 Cell Line | EDJ-KQ3112 | Human | 23012 | Details Get a Quote |
| STK38L Knockout A-549 Cell Line | EDJ-KQ24452 | Human | 23012 | Details Get a Quote |
| STK38L Knockout HCT 116 Cell Line | EDJ-KQ24453 | Human | 23012 | Details Get a Quote |
| STK38L Knockout HeLa Cell Line | EDJ-KQ24454 | Human | 23012 | Details Get a Quote |
| STK38L Knockout HAP1 Cell Line | EDC07901 | Human | 23012 | Details Get a Quote |
Displaying Records 1 To 5 Of 5 Records
